cobas^® HCV

Every day, approximately 3,000 people die from the consequences of viral hepatitis, and 1.1 million people every year¹ Roche is committed to fighting viral hepatitis with effective diagnosis and monitoring. For hepatitis C, cobas^® HCV for use on the cobas ^® 4800 System, offers precise, dual-probe HCV viral load testing to accurately identify disease and determine patient response to treatment.

A quantitative hepatitis C virus (HCV) RNA test must be able to tolerate sequence mismatches for accurate and reliable results. The combination of error-prone RNA replication and a high rate of virus production results in extreme genetic variability of HCV. Clinicians rely on regular HCV viral load assessment to achieve an optimal treatment outcome.

The cobas® HCV quantitative nucleic acid test delivers robust, clinically relevant assay performance based on the proprietary dual-probe assay design from Roche. cobas® HCV is designed to deliver high sensitivity to meet the requirements of current and future chronic hepatitis C therapies combined with an efficient workflow for laboratories.

The innovative, state-of-the-art dual-probe HCV viral load assay precisely distinguishes true signals from background noise leading to more accurate quantification of viral loads.

• Accurate detection and quantification of HCV genotypes 1 through 6
• Clinically validated for use with new HCV therapies
• Optimised clinical decisions through precise HCV viral load assessment
• Accurate HCV RNA viral load results are important for monitoring patients treated with the DAAs to decide on continuation of therapy and assess treatment success
• The Roche HCV dual-probe assay helps clinicians to better manage HCV patients facilitating optimized clinical decision